Results 11 to 20 of about 8,763,296 (354)

Inflammation and tumor progression: signaling pathways and targeted intervention

open access: yesSignal Transduction and Targeted Therapy, 2021
Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes.
Huakan Zhao   +6 more
semanticscholar   +1 more source

TIMER2.0 for analysis of tumor-infiltrating immune cells

open access: yesNucleic Acids Res., 2020
Tumor progression and the efficacy of immunotherapy are strongly influenced by the composition and abundance of immune cells in the tumor microenvironment.
Taiwen Li   +7 more
semanticscholar   +1 more source

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

open access: yesMolecular Cancer, 2021
Cancer-associated fibroblasts (CAFs), a stromal cell population with cell-of-origin, phenotypic and functional heterogeneity, are the most essential components of the tumor microenvironment (TME).
Xiaoqi Mao   +9 more
semanticscholar   +1 more source

Tumor angiogenesis

open access: yesAdvances in Cancer Research, 2020
The hypothesis that tumors are angiogenesis dependent has, in the past decade, generated new investigations designed to elucidate the mechanism of angiogenesis itself. Many laboratories are now engaged in this pursuit. Some are studying angiogenesis that
Farah Fatmawati, Whendy Wijaksono
semanticscholar   +1 more source

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer

open access: yesBMC Cancer, 2023
Background Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells.
Shane O’Brien   +8 more
doaj   +1 more source

Indocyanine green near-infrared imaging-guided lymph node dissection during oesophageal cancer surgery: A single-centre experience

open access: yesFrontiers in Surgery, 2023
ObjectiveThis study aimed to investigate the feasibility of using indocyanine green (ICG) near-infrared (NIR) imaging during lymphadenectomy for oesophageal cancer.MethodsEighty-seven patients with primary oesophageal cancer were enrolled in this study ...
Saihua Chen   +9 more
doaj   +1 more source

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

open access: yesCellular & Molecular Immunology, 2020
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but
Yuanyuan Zhang, Zemin Zhang
semanticscholar   +1 more source

Cancer therapeutic potential of combinatorial immuno- and vaso-modulatory interventions [PDF]

open access: yes, 2015
Currently, most of the basic mechanisms governing tumor-immune system interactions, in combination with modulations of tumor-associated vasculature, are far from being completely understood.
Alfonso, J. C. L.   +5 more
core   +3 more sources

PHF5A facilitates the development and progression of gastric cancer through SKP2-mediated stabilization of FOS

open access: yesJournal of Translational Medicine, 2023
Background Gastric cancer (GC) is the fifth most common cancer and the third most common cause of cancer death worldwide. Plant homeodomain (PHD)-finger domain protein PHF5A has been demonstrated to play a promoting role in a variety of cancers.
Zhandong Zhang   +5 more
doaj   +1 more source

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells [PDF]

open access: yes, 2016
Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens.
Bear, Harry D.   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy